Shares of Zafgen Inc. (NASDAQ:ZFGN) were up 3.7% during mid-day trading on Monday . The company traded as high as $3.17 and last traded at $3.06, with a volume of 675,584 shares trading hands. The stock had previously closed at $2.95.

A number of analysts have recently issued reports on ZFGN shares. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $19.00 price target on shares of Zafgen in a report on Tuesday, April 5th. Canaccord Genuity set a $4.00 price objective on shares of Zafgen and gave the stock a “hold” rating in a research note on Thursday. Leerink Swann reiterated a “hold” rating and issued a $6.00 price objective on shares of Zafgen in a research note on Monday, April 11th. FBR & Co reiterated a “buy” rating and issued a $20.00 price objective on shares of Zafgen in a research note on Monday, April 4th. Finally, Cowen and Company cut shares of Zafgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 20th. Six analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Zafgen currently has a consensus rating of “Hold” and an average target price of $9.69.

The stock’s market cap is $85.09 million. The company has a 50 day moving average price of $6.07 and a 200-day moving average price of $6.51.

Zafgen (NASDAQ:ZFGN) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.09. During the same quarter last year, the company earned ($0.53) earnings per share. On average, equities analysts forecast that Zafgen Inc. will post ($2.62) earnings per share for the current year.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.